Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.61 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21731181 | 0.91 | ADORA2A (0.61) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21731211 | 0.91 | ADORA2A (0.62) | ADORA2AADORA2BADORA1MEN1KMT2A | |
| SCHEMBL21731083 | 0.90 | ADORA2A (0.61) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21731079 | 0.90 | ADORA2A (0.57) | ADORA2AADORA2BADORA1MEN1KMT2A | |
| SCHEMBL21731126 | 0.89 | ADORA2A (0.63) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21731088 | 0.89 | ADORA2A (0.61) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21731022 | 0.89 | ADORA2A (0.59) | ADORA2AADORA2BADORA1MEN1KMT2A | |
| SCHEMBL21731271 | 0.87 | ADORA2A (0.57) | ADORA2AADORA2BADORA1 | |
| SCHEMBL21731159 | 0.87 | ADORA2A (0.66) | ADORA2AADORA2BADORA1MEN1KMT2A | |
| SCHEMBL21731157 | 0.86 | ADORA2A (0.68) | ADORA2AADORA2BADORA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11649239-B2 | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) | MEDSHINE DISCOVERY INC. (CN) | 2023-05-16 | — | — | US | claimed |
| US-11649239-B2 | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) | MEDSHINE DISCOVERY INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649239-B2 | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) | MEDSHINE DISCOVERY INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-11649239-B2 | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) | MEDSHINE DISCOVERY INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| EP-3611174-B1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2022-06-08 | — | — | EP | disclosed |
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | MEDSHINE DISCOVERY INC. (CN) | 2021-09-14 | — | — | US | disclosed |
| US-11066411-B2 | — | — | 2021-07-20 | — | — | US | disclosed |
| US-20210094957-A1 | CRYSTAL FORM AND SALT TYPE OF TRIAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2021-04-01 | — | — | US | disclosed |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2020-04-30 | — | — | US | disclosed |
| EP-3611174-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | Medshine Discovery Inc. (CN) | 2020-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117899-B2 | [1,2,4]triazolo[1,5-c]pyrimidine derivative as A2A receptor inhibitor | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
| US-11066411-B2 | — | ADORA2A, ADORA1, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA1 2/4885 |
| US-11649239-B2 | Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1) | ADORA2A, ADORA1, HTR5A | ADORA2A 1/4885ADORA2B 8/4885ADORA1 2/4885 |
| US-20200131184-A1 | [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE DERIVATIVE AS A2A RECEPTOR INHIBITOR | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 4/4885ADORA1 2/4885 |
| US-20210094957-A1 | CRYSTAL FORM AND SALT TYPE OF TRIAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREOF | ADORA2A, ADORA1, ADORA3 | ADORA2A 1/4885ADORA2B 7/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.